IQVIA (NYSE:IQV) Lowered to Hold Rating by StockNews.com

IQVIA (NYSE:IQV) was downgraded by equities research analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday.

IQV has been the subject of several other reports. JPMorgan Chase & Co. decreased their price objective on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a report on Tuesday, November 5th. Redburn Atlantic assumed coverage on shares of IQVIA in a report on Monday, October 14th. They set a “buy” rating and a $276.00 price objective for the company. BTIG Research decreased their price objective on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a report on Friday, November 1st. Evercore ISI decreased their price target on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Finally, Deutsche Bank Aktiengesellschaft decreased their price target on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a report on Friday, November 1st. Five equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $256.50.

IQVIA Price Performance

Shares of IQV stock opened at $201.44 on Thursday. The firm has a market cap of $36.56 billion, a P/E ratio of 26.44, a P/E/G ratio of 2.10 and a beta of 1.51. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. IQVIA has a 1-year low of $187.62 and a 1-year high of $261.73. The firm has a fifty day moving average of $220.36 and a two-hundred day moving average of $226.57.

Institutional Trading of IQVIA

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Capital Performance Advisors LLP bought a new stake in shares of IQVIA during the 3rd quarter worth about $27,000. Park Place Capital Corp bought a new stake in shares of IQVIA in the 3rd quarter worth approximately $28,000. Versant Capital Management Inc raised its holdings in shares of IQVIA by 733.3% in the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after purchasing an additional 110 shares in the last quarter. Opal Wealth Advisors LLC bought a new stake in shares of IQVIA in the 2nd quarter worth approximately $27,000. Finally, Itau Unibanco Holding S.A. bought a new stake in shares of IQVIA in the 2nd quarter worth approximately $29,000. 89.62% of the stock is currently owned by institutional investors.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.